Daci E, Udagawa N, Martin T J, Bouillon R, Carmeliet G
Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Katholieke Universiteit, Leuven, Belgium.
J Bone Miner Res. 1999 Jun;14(6):946-52. doi: 10.1359/jbmr.1999.14.6.946.
The plasminogen/plasmin proteolytic cascade plays an important role in extracellular matrix remodeling. The presence of the two plasminogen activators (PAs), tissue-type plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA), and their inhibitor type 1 (PAI-1) in bone cells, suggests a role in one or more aspects of bone resorption such as osteoclast formation, mineral dissolution, and degradation of the organic matrix. These different processes were assayed in vitro using cells derived from mice with either tPA (tPA-/-), uPA (uPA-/-), PAI-1 (PAI-1-/-) inactivation or with a combined inactivation (tPA-/-:uPA-/-) and compared with wild-type mice (WT). First, osteoclast formation, assessed by investigating the number and characteristics of tartrate-resistant acid phosphatase-positive multinucleated cells formed in cocultures of primary osteoblasts and bone marrow cells treated with 1alpha,25-dihydroxyvitamin D3, was not different between the different cell types. Second, dentine resorption, an assay for osteoclast activity, was not affected by the combined deficiency of both tPA and uPA. Finally, the ability to degrade nonmineralized bone-like matrix was however, significantly reduced in tPA-/-:uPA-/- cells compared with WT cells (28.1 +/- 0.6%, n = 6 vs. 56.4 +/- 3.1%, n = 6, respectively, p < 0.0001). Surprisingly, collagen proteolysis by bone cells was not dependent on the presence of plasmin as suggested by degradation assays performed on type I 3H-collagen films. Taken together, these data suggest that the plasminogen activator/plasmin system is not required for osteoclast formation, nor for the resorption of the mineral phase, but is involved in the removal of noncollagenous proteins present in the nonmineralized bone matrix.
纤溶酶原/纤溶酶蛋白水解级联反应在细胞外基质重塑中起重要作用。骨细胞中存在两种纤溶酶原激活剂(PAs),即组织型纤溶酶原激活剂(tPA)和尿激酶型纤溶酶原激活剂(uPA),以及它们的1型抑制剂(PAI-1),这表明其在骨吸收的一个或多个方面发挥作用,如破骨细胞形成、矿物质溶解和有机基质降解。使用来自tPA(tPA-/-)、uPA(uPA-/-)、PAI-1(PAI-1-/-)失活或联合失活(tPA-/-:uPA-/-)小鼠的细胞在体外对这些不同过程进行了测定,并与野生型小鼠(WT)进行比较。首先,通过研究用1α,25-二羟基维生素D3处理的原代成骨细胞和骨髓细胞共培养物中形成的抗酒石酸酸性磷酸酶阳性多核细胞的数量和特征来评估破骨细胞形成,不同细胞类型之间没有差异。其次,牙本质吸收作为破骨细胞活性的一种测定方法,不受tPA和uPA联合缺乏的影响。然而,与WT细胞相比,tPA-/-:uPA-/-细胞降解非矿化骨样基质的能力显著降低(分别为28.1±0.6%,n = 6和56.4±3.1%,n = 6,p < 0.0001)。令人惊讶的是,如对I型3H-胶原膜进行的降解测定所示,骨细胞的胶原蛋白水解并不依赖于纤溶酶的存在。综上所述,这些数据表明纤溶酶原激活剂/纤溶酶系统对于破骨细胞形成不是必需的,对于矿质相的吸收也不是必需的,但参与了非矿化骨基质中存在的非胶原蛋白的去除。